Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3098923rdf:typepubmed:Citationlld:pubmed
pubmed-article:3098923lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:3098923lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:3098923lifeskim:mentionsumls-concept:C1096063lld:lifeskim
pubmed-article:3098923lifeskim:mentionsumls-concept:C0080356lld:lifeskim
pubmed-article:3098923lifeskim:mentionsumls-concept:C1579762lld:lifeskim
pubmed-article:3098923lifeskim:mentionsumls-concept:C0009491lld:lifeskim
pubmed-article:3098923lifeskim:mentionsumls-concept:C1696465lld:lifeskim
pubmed-article:3098923lifeskim:mentionsumls-concept:C0072076lld:lifeskim
pubmed-article:3098923pubmed:issue11lld:pubmed
pubmed-article:3098923pubmed:dateCreated1987-2-17lld:pubmed
pubmed-article:3098923pubmed:abstractTextA three way single blind cross-over comparison of progabide, valproate and placebo, as adjunctive therapy, was undertaken in 64 patients with therapy-resistant partial and generalised seizures. The study was not completed because of the incidence of elevated hepatic enzymes on progabide. Analysis of efficacy showed progabide to be inferior to valproate against all seizure types, particularly against tonic-clonic seizures. Valproate was superior to placebo against all seizure types, partial and tonic-clonic seizures. Progabide did not differ significantly from placebo in any instance. In addition progabide caused elevation of hepatic enzymes which was symptomatic in one case, and was associated with an interaction with phenytoin which resulted in symptoms of intoxication in some cases.lld:pubmed
pubmed-article:3098923pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3098923pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3098923pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3098923pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3098923pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3098923pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3098923pubmed:languageenglld:pubmed
pubmed-article:3098923pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3098923pubmed:citationSubsetIMlld:pubmed
pubmed-article:3098923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3098923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3098923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3098923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3098923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3098923pubmed:statusMEDLINElld:pubmed
pubmed-article:3098923pubmed:monthNovlld:pubmed
pubmed-article:3098923pubmed:issn0022-3050lld:pubmed
pubmed-article:3098923pubmed:authorpubmed-author:ChadwickDDlld:pubmed
pubmed-article:3098923pubmed:authorpubmed-author:CrawfordPPlld:pubmed
pubmed-article:3098923pubmed:issnTypePrintlld:pubmed
pubmed-article:3098923pubmed:volume49lld:pubmed
pubmed-article:3098923pubmed:ownerNLMlld:pubmed
pubmed-article:3098923pubmed:authorsCompleteYlld:pubmed
pubmed-article:3098923pubmed:pagination1251-7lld:pubmed
pubmed-article:3098923pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:3098923pubmed:meshHeadingpubmed-meshheading:3098923-...lld:pubmed
pubmed-article:3098923pubmed:meshHeadingpubmed-meshheading:3098923-...lld:pubmed
pubmed-article:3098923pubmed:meshHeadingpubmed-meshheading:3098923-...lld:pubmed
pubmed-article:3098923pubmed:meshHeadingpubmed-meshheading:3098923-...lld:pubmed
pubmed-article:3098923pubmed:meshHeadingpubmed-meshheading:3098923-...lld:pubmed
pubmed-article:3098923pubmed:meshHeadingpubmed-meshheading:3098923-...lld:pubmed
pubmed-article:3098923pubmed:meshHeadingpubmed-meshheading:3098923-...lld:pubmed
pubmed-article:3098923pubmed:meshHeadingpubmed-meshheading:3098923-...lld:pubmed
pubmed-article:3098923pubmed:meshHeadingpubmed-meshheading:3098923-...lld:pubmed
pubmed-article:3098923pubmed:meshHeadingpubmed-meshheading:3098923-...lld:pubmed
pubmed-article:3098923pubmed:meshHeadingpubmed-meshheading:3098923-...lld:pubmed
pubmed-article:3098923pubmed:meshHeadingpubmed-meshheading:3098923-...lld:pubmed
pubmed-article:3098923pubmed:meshHeadingpubmed-meshheading:3098923-...lld:pubmed
pubmed-article:3098923pubmed:meshHeadingpubmed-meshheading:3098923-...lld:pubmed
pubmed-article:3098923pubmed:meshHeadingpubmed-meshheading:3098923-...lld:pubmed
pubmed-article:3098923pubmed:year1986lld:pubmed
pubmed-article:3098923pubmed:articleTitleA comparative study of progabide, valproate, and placebo as add-on therapy in patients with refractory epilepsy.lld:pubmed
pubmed-article:3098923pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3098923pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:3098923pubmed:publicationTypeControlled Clinical Triallld:pubmed
pubmed-article:3098923pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3098923lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3098923lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3098923lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3098923lld:pubmed